BBOT · BridgeBio Oncology Therapeutics, Inc.
$9.60
+0.65 (+7.26%)
At close · Aug 19
Market Cap
$717.56M
Shares
80.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.60
Open$9.16
Day$9.14–9.72
52W close$7.12–13.73
Avg vol 30d308K
Short int5.8M · 7.3% float · 20.8d
Short vol71%
Last earningsMar 5, 2026
DataFeb 2024–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
+15%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
38%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−6%
trailing
YTD return
−23%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.27% of float · ▲ +2.4% MoM · 20.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 1-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
EPS growth
+100%
Y/Y
Free cash flow
$-114.5M
Balance sheet
$373.4M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
+15%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
38%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.27% of float · ▲ +2.4% MoM · 20.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $10 · 38%
Range high $14
vs 200-day avg -4%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBOT
this stock
BridgeBio Oncology Therapeutics, Inc.
|
$717.56M | -23.3% | — | — | 7.3% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBOT | +1.9% | +7.9% | -6.3% | +18.7% | -23.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.4% | +5.0% | -17.9% | +15.7% | -36.1% |
Key facts
CIK
1869105
CUSIP
107924102
13F (30d)
66 filings
65 filers
Visit website
Investor relations